CN114176212A - Chafing dish ingredient capable of reducing uric acid and improving immunity and preparation method thereof - Google Patents
Chafing dish ingredient capable of reducing uric acid and improving immunity and preparation method thereof Download PDFInfo
- Publication number
- CN114176212A CN114176212A CN202111480327.XA CN202111480327A CN114176212A CN 114176212 A CN114176212 A CN 114176212A CN 202111480327 A CN202111480327 A CN 202111480327A CN 114176212 A CN114176212 A CN 114176212A
- Authority
- CN
- China
- Prior art keywords
- uric acid
- citrus
- parts
- chafing dish
- improving immunity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title claims abstract description 56
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title claims abstract description 55
- 229940116269 uric acid Drugs 0.000 title claims abstract description 55
- 230000001603 reducing effect Effects 0.000 title claims abstract description 41
- 230000036039 immunity Effects 0.000 title claims abstract description 38
- 239000004615 ingredient Substances 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 241000207199 Citrus Species 0.000 claims abstract description 61
- 235000020971 citrus fruits Nutrition 0.000 claims abstract description 61
- 240000000759 Lepidium meyenii Species 0.000 claims abstract description 32
- 235000000421 Lepidium meyenii Nutrition 0.000 claims abstract description 32
- 235000012902 lepidium meyenii Nutrition 0.000 claims abstract description 32
- 241000123113 Phellinus igniarius Species 0.000 claims abstract description 28
- 239000000284 extract Substances 0.000 claims abstract description 21
- 241001248610 Ophiocordyceps sinensis Species 0.000 claims abstract description 17
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 16
- 240000000249 Morus alba Species 0.000 claims abstract description 16
- 239000006041 probiotic Substances 0.000 claims abstract description 14
- 235000018291 probiotics Nutrition 0.000 claims abstract description 14
- 241000190633 Cordyceps Species 0.000 claims abstract description 12
- 238000001035 drying Methods 0.000 claims abstract description 9
- 230000002829 reductive effect Effects 0.000 claims abstract description 9
- 230000001954 sterilising effect Effects 0.000 claims abstract description 9
- 238000000855 fermentation Methods 0.000 claims abstract description 8
- 230000004151 fermentation Effects 0.000 claims abstract description 8
- 239000002994 raw material Substances 0.000 claims abstract description 7
- 238000001816 cooling Methods 0.000 claims abstract description 6
- 238000011049 filling Methods 0.000 claims abstract description 6
- 238000002156 mixing Methods 0.000 claims abstract description 6
- 238000004806 packaging method and process Methods 0.000 claims abstract description 6
- 238000004080 punching Methods 0.000 claims abstract description 6
- 238000002791 soaking Methods 0.000 claims abstract description 6
- 238000005303 weighing Methods 0.000 claims abstract description 6
- 238000004140 cleaning Methods 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 30
- 241000894006 Bacteria Species 0.000 claims description 14
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 12
- 241000193749 Bacillus coagulans Species 0.000 claims description 8
- 229940054340 bacillus coagulans Drugs 0.000 claims description 8
- 235000014655 lactic acid Nutrition 0.000 claims description 6
- 239000004310 lactic acid Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 238000011081 inoculation Methods 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 238000002137 ultrasound extraction Methods 0.000 claims description 2
- 241001672694 Citrus reticulata Species 0.000 claims 1
- 230000008901 benefit Effects 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 19
- 239000000243 solution Substances 0.000 description 13
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 12
- 201000001431 Hyperuricemia Diseases 0.000 description 11
- 239000000126 substance Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 8
- 230000009286 beneficial effect Effects 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 229930013930 alkaloid Natural products 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 241000186660 Lactobacillus Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 150000003797 alkaloid derivatives Chemical class 0.000 description 3
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 3
- 229960003459 allopurinol Drugs 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 229940039696 lactobacillus Drugs 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 208000030159 metabolic disease Diseases 0.000 description 3
- 150000008442 polyphenolic compounds Chemical class 0.000 description 3
- 235000013824 polyphenols Nutrition 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- RYYCJUAHISIHTL-UHFFFAOYSA-N 5-azaorotic acid Chemical compound OC(=O)C1=NC(=O)NC(=O)N1 RYYCJUAHISIHTL-UHFFFAOYSA-N 0.000 description 2
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- KQLDDLUWUFBQHP-UHFFFAOYSA-N Cordycepin Natural products C1=NC=2C(N)=NC=NC=2N1C1OCC(CO)C1O KQLDDLUWUFBQHP-UHFFFAOYSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 108010093894 Xanthine oxidase Proteins 0.000 description 2
- 102100033220 Xanthine oxidase Human genes 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- MDKCFLQDBWCQCV-UHFFFAOYSA-N benzyl isothiocyanate Chemical compound S=C=NCC1=CC=CC=C1 MDKCFLQDBWCQCV-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 description 2
- OFEZSBMBBKLLBJ-UHFFFAOYSA-N cordycepine Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000000916 dilatatory effect Effects 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 description 2
- 229930019673 naringin Natural products 0.000 description 2
- 229940052490 naringin Drugs 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 229950000193 oteracil Drugs 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000002633 protecting effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000019163 vitamin B12 Nutrition 0.000 description 2
- 239000011715 vitamin B12 Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002482 Angiosclerosis Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 206010006500 Brucellosis Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241000019229 Dinia Species 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 241000123392 Hymenochaetaceae Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- 241000589901 Leptospiraceae Species 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- QAADZYUXQLUXFX-UHFFFAOYSA-N N-phenylmethylthioformamide Natural products S=CNCC1=CC=CC=C1 QAADZYUXQLUXFX-UHFFFAOYSA-N 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 241000123107 Phellinus Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010038084 Rectocele Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 206010041235 Snoring Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 241000001727 Tropicoporus linteus Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 125000004383 glucosinolate group Chemical group 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 201000001037 lung lymphoma Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 235000017924 poor diet Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 229910052701 rubidium Inorganic materials 0.000 description 1
- IGLNJRXAVVLDKE-UHFFFAOYSA-N rubidium atom Chemical compound [Rb] IGLNJRXAVVLDKE-UHFFFAOYSA-N 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009044 synergistic interaction Effects 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000009492 vitamin B5 Nutrition 0.000 description 1
- 239000011675 vitamin B5 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/10—Natural spices, flavouring agents or condiments; Extracts thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
- A61K36/068—Cordyceps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention discloses a hotpot ingredient capable of reducing uric acid and improving immunity, which comprises the following raw materials in parts by weight: 10-12 parts of citrus pith peel, 4-6 parts of cordyceps sinensis, 8-10 parts of mulberry twigs, 12-15 parts of maca and 10-15 parts of phellinus igniarius; the preparation method comprises the following steps: (1) selecting mature oranges with uniform size, cleaning, opening the top of the orange, taking out orange pulp, and punching; (2) weighing; (3) mixing pericarpium Citri Reticulatae Chachiensis, Cordyceps and ramulus Mori, ultrasonic extracting, and concentrating the extractive solution under reduced pressure; (4) slicing maca and phellinus igniarius, filling the sliced maca and phellinus igniarius into a hollow citrus main body, then soaking the hollow citrus main body in an active extract concentrated solution, sterilizing at high temperature, inoculating high-temperature-resistant probiotics after cooling, taking out after fermentation, covering a top cover of citrus, drying at low temperature, taking out, and packaging to obtain the product. The invention has the advantages of simple preparation process of the ingredients of the chafing dish for reducing uric acid and improving immunity, low production cost and good industrial application prospect.
Description
Technical Field
The invention relates to the technical field of food processing, in particular to a chafing dish ingredient for reducing uric acid and improving immunity and a preparation method thereof.
Background
Along with the rapid development of social economy and the poor diet and living habits of partial crowds, the hyperuricemia population and gout patients in China are increasing in recent years. Among them, hyperuricemia has become another common metabolic disease after diabetes, and is one of the important causes threatening human health at present.
Uric acid is the main metabolite of animals, and has the chemical formula of C5H4N4O3Slightly soluble in water and prone to form crystals. The product in normal human urine is mainly urea and contains a small amount of uric acid. Uric acid is the end product of purine metabolism, is trioxypurine, and has an alcohol formula with weak acidity. Uric acid produced by oxidation of various purines is excreted with urine. Normally, uric acid in the body is about 1200mg, about 600mg is newly generated every day, and 600mg is excreted and kept in a balanced state. However, if too much uric acid is produced in the body and excretion is delayed or the uric acid excretion mechanism is degraded, the uric acid in the body is retained too much, and when the blood uric acid concentration is more than 7 mg/dl, the body fluid of the human body turns sour, and gout can be caused if the human body is left for a long time.
Hyperuricemia is a metabolic disorder syndrome caused by purine metabolic disorder in vivo, and refers to hyperuricemia, namely that under a normal purine diet state, the fasting blood uric acid level of two times on non-same day is higher than 420 mu mol/L in men and higher than 360 mu mol/L in women. According to the reports of the prevalence rate of hyperuricemia in various places in recent years, about 1.2 hundred million hyperuricemia people in China currently account for about 10 percent of the total population, and the advanced age is middle-aged and old men and postmenopausal women, but the hyperuricemia is in a trend of being younger in recent years.
The chafing dish is a popular food, is suitable for people of all ages and is a good product in winter. However, the high purine content in chafing dish can easily cause hyperuricemia when people frequently eat the chafing dish. The existing chafing dish purine control method has no better method for solving the problem of purine increase in the chafing dish except that the food material containing low purine is selected.
Therefore, the problem to be solved by the technical personnel in the field is how to develop the chafing dish ingredient for reducing uric acid and improving immunity and the preparation method thereof.
Disclosure of Invention
In view of the above, the invention aims to provide a chafing dish ingredient for reducing uric acid and improving immunity and a preparation method thereof, so as to solve the defects in the prior art.
In order to achieve the purpose, the invention adopts the following technical scheme:
a chafing dish ingredient for reducing uric acid and improving immunity comprises the following raw materials in parts by weight: 10-12 parts of citrus pith peel, 4-6 parts of cordyceps sinensis, 8-10 parts of mulberry twigs, 12-15 parts of maca and 10-15 parts of phellinus igniarius; preferably: 11 parts of citrus pith peel, 5 parts of cordyceps sinensis, 9 parts of mulberry twig, 13 parts of maca and 12 parts of phellinus igniarius.
In the invention:
citrus is a plant of the genus Citrus of the family Rutaceae. Modern pharmacological research considers that: the content of carotene, vitamin C and vitamin P in the orange peel is higher than that of pulp. The orange peel also contains thiamine, riboflavin, volatile oil and flavonoids, and the volatile oil in the orange peel has the effects of stimulating the digestive tract, increasing gastric secretion, promoting gastrointestinal motility, invigorating stomach and dispelling pathogenic wind. The flavone has effects of dilating coronary artery and increasing coronary artery blood flow. In addition, the orange peel also has the effects of diminishing inflammation, resisting ulcer, inhibiting bacteria, benefiting gallbladder and the like. The vitamin P in the orange peel has obvious curative effect on the angiosclerosis. Scientists have found that they extract an anti-cancer substance from citrus peel and have also found a blood pressure lowering component in this substance. The anticancer substance is widely present in lemon peel and citrus peel, and animal experiments show that the life of cancer-suffering animals taking the anticancer substance can be obviously prolonged.
Cordyceps, Cordyceps sinensis, is a fungus of the genus Leptospira of the family Leptospiraceae. The chemical components are as follows: nucleotide: cordycepin, adenosine, uracil, etc.; ② cordyceps polysaccharide: d mannitol (cordycepic acid); ③ sterols: ergosterol, cholesterol, and the like; in addition, crude protein, fat, fatty acid, vitamin B12, etc. are contained; cordyceps polysaccharide has effects of regulating immunity, reducing blood sugar, and resisting tumor; the nucleotide components such as cordycepin have antibacterial and antitumor effects. The pharmacological action is as follows: firstly, immune regulation is carried out, and cordyceps polysaccharide has bidirectional regulation effect; ② relieving cough, eliminating phlegm and relieving asthma, the Cordyceps sinensis and Cordyceps sinensis have obvious effect of dilating bronchus; ③ the sexual dysfunction of the male mice in the regulation and recovery test under the action of male hormone; fourthly, the cordyceps sinensis has an anti-tumor effect, and has an inhibition effect on primary focuses, spontaneous lung metastasis and lymphoma of the lung cancer of the mice; in addition, it has antibacterial, anti-tumor, antifatigue, antiaging, myocardial ischemia resisting, and kidney protecting effects. The functions and indications are as follows: sweet and mild; tonifying kidney, benefiting lung, stopping bleeding, and eliminating phlegm; can be used for treating kidney essence deficiency, sexual impotence, spermatorrhea, soreness of waist and knees, cough, asthma, and hemoptysis.
The mulberry twig is a generic name of branches and leaves, mulberry twigs and tender mulberry twigs of a mulberry tree. The ramulus mori contains a plurality of active ingredients, such as snore compounds, alkaloids, free sugar, plant sugar, pectin and the like, has wide application in the field of modern medicine, and can treat and relieve various diseases. The traditional Chinese medicine considers that mulberry twigs are bitter in taste and neutral in flavor, enter liver meridian, have the effects of dispelling wind and dredging collaterals, and are commonly used for treating rheumatic arthralgia and limb spasm, especially for limb paralysis. The mulberry twig has the antibacterial effect, can improve the lymphocyte transformation rate, is effective in treating chronic brucellosis, and has the obvious blood pressure reducing effect.
Maca, i.e. maca. The chemical composition of maca dry root is firstly and systematically obtained by the italian scientist DiniA in 1994: protein content of more than 10% (protein content of maca variety in huning lakeside more than 14%), and carbohydrate of 59%; 8.5% of fiber contains abundant mineral substances such as zinc, calcium, iron, titanium, rubidium, potassium, sodium, copper, manganese, magnesium, strontium, phosphorus, iodine, etc., contains vitamins C, B1, B2, B6, A, E, B12 and B5, has low fat content but mostly unsaturated fatty acid, linoleic acid and linolenic acid with content of more than 53%, and natural active components including alkaloid, glucosinolate and its decomposition products such as benzyl isothiocyanate, sterol, polyphenol, etc. In 1999, american scientists discovered that maca contains two new plant active ingredients, macamides and macaenes, and determined that these two substances have a significant effect on balancing the secretion of hormones in the human body, so maca is also known as a natural hormone engine.
Phellinus linteus of Phellinus genus of Hymenochaetaceae family. Slightly bitter taste and cold nature. It enters liver and kidney meridians. The medicinal effective components of the phellinus igniarius are mostly expressed in the effects of regulating immunity, resisting tumors, resisting oxidation, reducing blood sugar, protecting liver, inhibiting bacteria and diminishing inflammation and the like, and have the effects of promoting blood circulation, stopping bleeding, relieving fluid retention and stopping diarrhea. It is commonly used for metrorrhagia, stranguria with blood, rectocele, diarrhea, leukorrhagia, amenorrhea, abdominal mass, retained fluid, spleen deficiency and diarrhea.
A preparation method of a chafing dish ingredient for reducing uric acid and improving immunity specifically comprises the following steps:
(1) selecting mature oranges with uniform sizes, cleaning and opening the top of the mature oranges to obtain an orange top cover; taking out citrus pulp to obtain a hollow citrus main body; punching holes on the citrus hollow main body to respectively obtain a citrus perforated peel and a citrus perforated hollow main body;
(2) weighing citrus pith, cordyceps sinensis, ramulus mori, maca and phellinus igniarius according to the parts by weight of the ingredients of the chafing dish for reducing uric acid and improving immunity;
(3) mixing pericarpium Citri Reticulatae Chachiensis, Cordyceps and ramulus Mori, extracting with ultrasonic wave, and concentrating the extractive solution under reduced pressure to obtain active extract concentrated solution;
(4) slicing maca and phellinus igniarius, filling the sliced maca and phellinus igniarius into a hollow main body of an orange, then soaking the orange in an active extract concentrated solution, sterilizing at high temperature, inoculating high-temperature-resistant probiotics after cooling, taking out after fermentation, covering a top cover of the orange, drying at low temperature, taking out and packaging to obtain the uric acid-reducing and immunity-improving hotpot ingredient.
Further, in the step (3), the solvent for ultrasonic extraction is ethanol, the power is 40-50KHz, and the time is 5-8 min.
The further technical scheme has the beneficial effects that the cavitation effect of the ultrasonic wave is utilized, so that the active ingredients in the mixture of the citrus pith skin, the cordyceps sinensis and the mulberry twigs can be fully extracted.
Further, in the step (3), the extract is concentrated under reduced pressure until the extract has no alcohol smell.
The further technical scheme has the beneficial effects that through the reduced pressure concentration, the ethanol is completely evaporated, and the concentration of the active extract is improved through concentration.
Further, in the step (4), the temperature of the high-temperature sterilization is 121-.
The beneficial effect of adopting the further technical scheme is that bacteria can be killed through high-temperature sterilization, and the growth of mixed bacteria after the probiotics are inoculated is prevented.
Further, in the step (4), the high-temperature resistant probiotics comprise bacillus coagulans and lactic acid bacteria, and the inoculation amount is 8-12%.
The beneficial effects of the further technical scheme are that the bacillus coagulans can inhibit harmful bacteria after fermentation culture and promote the growth and reproduction of beneficial bacteria such as lactic acid bacteria, bifidobacteria and the like; the lactobacillus can promote normal metabolism, decompose protein and saccharide in food to synthesize vitamin, and promote gastrointestinal absorption of nutrient substances. After being eaten, the probiotic is favorable for restoring the microecological balance of the gastrointestinal tract, and the defect that probiotics in common products cannot resist high temperature is overcome.
Further, in the step (3), the fermentation temperature is 25-30 ℃ and the fermentation time is 24-48 min.
The beneficial effects of the further technical scheme are that after the bacillus coagulans and the lactic acid bacteria are fermented, the product can generate a synergistic interaction effect, so that the total number of viable bacteria of the probiotics, the contents of active ingredients such as polyphenol, alkaloid, volatile oil, naringin and the like are increased, a large amount of vitamins, prebiotics and the like necessary for human nutrition are generated, and the product is easier to absorb and utilize by a human body.
Further, in the step (4), the temperature of the low-temperature drying is 45-50 ℃, and the time is 240-.
The beneficial effect of adopting the further technical scheme is that through low-temperature drying, the nutritional active ingredients of the product can be better kept, and the form of the product can be better kept.
According to the technical scheme, compared with the prior art, the invention has the following beneficial effects:
1. according to the invention, ramulus mori and citrus pith are selected as raw materials to extract active ingredients for reducing uric acid, phellinus igniarius is added, the active extract and phellinus igniarius extract can be synergized in a synergistic manner when a hot pot is boiled, and the active ingredients can inhibit the activity of xanthine oxidase, so that xanthine is prevented from generating uric acid under the action of the xanthine oxidase, and the effect of reducing uric acid is more remarkable. In addition, the cordyceps extract and the maca extract can be synergized to further improve the immunity of the human body.
2. According to the invention, after the maca and the phellinus igniarius are inoculated with probiotics, the fermented product and the active extracts of the ramulus mori, the cordyceps and the citrus pith skin can generate a synergistic effect, so that the total number of viable bacteria of the probiotics, the contents of active ingredients such as polyphenol, alkaloid and naringin are increased, and the effect of reducing uric acid is also obviously enhanced.
3. The invention has the advantages of simple preparation process of the ingredients of the chafing dish for reducing uric acid and improving immunity, low production cost and good industrial application prospect.
Detailed Description
The technical solutions in the embodiments of the present invention are clearly and completely described below, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1
The chafing dish ingredient for reducing uric acid and improving immunity comprises the following raw materials by weight: 11g of citrus pith peel, 5g of cordyceps sinensis, 9g of mulberry twigs, 13g of maca and 12g of phellinus igniarius;
the preparation method of the chafing dish ingredient for reducing uric acid and improving immunity specifically comprises the following steps:
(1) selecting mature oranges with uniform sizes, and opening the top of the mature oranges after the mature oranges are washed by running water to obtain an orange top cover; taking out citrus pulp to obtain a hollow citrus main body; punching holes on the citrus hollow main body to respectively obtain a citrus perforated peel and a citrus perforated hollow main body;
(2) weighing 11g of citrus pith peel, 5g of cordyceps sinensis, 9g of mulberry twigs, 13g of maca and 12g of phellinus igniarius according to the weight of the ingredients of the chafing dish for reducing uric acid and improving immunity;
(3) mixing pericarpium Citri Reticulatae Chachiensis, Cordyceps and ramulus Mori, extracting with ethanol under 45KHz power for 6min, and concentrating the extractive solution under reduced pressure until ethanol smell disappears to obtain active extract concentrated solution;
(4) slicing maca and phellinus igniarius, filling the sliced maca and phellinus igniarius into a hollow main body of a citrus, then soaking the hollow main body of the citrus in an active extract concentrated solution, sterilizing the hollow main body at a high temperature of 122 ℃ for 22min, cooling the hollow main body, inoculating 10% of high-temperature-resistant probiotics bacillus coagulans and lactobacillus, fermenting the hollow main body at a temperature of 28 ℃ for 36h, taking out the hollow main body, covering a top cover of the citrus, drying the hollow main body at a low temperature of 48 ℃ for 260min, taking out and packaging the hollow main body to obtain the chafing dish ingredient for reducing uric acid and improving immunity.
Example 2
The chafing dish ingredient for reducing uric acid and improving immunity comprises the following raw materials by weight: 10g of citrus pith peel, 4g of cordyceps sinensis, 8g of mulberry twig, 15g of maca and 15g of phellinus igniarius;
the preparation method of the chafing dish ingredient for reducing uric acid and improving immunity specifically comprises the following steps:
(1) selecting mature oranges with uniform sizes, and opening the top of the mature oranges after the mature oranges are washed by running water to obtain an orange top cover; taking out citrus pulp to obtain a hollow citrus main body; punching holes on the citrus hollow main body to respectively obtain a citrus perforated peel and a citrus perforated hollow main body;
(2) weighing 10g of citrus pith peel, 4g of cordyceps sinensis, 8g of mulberry twig, 15g of maca and 15g of phellinus igniarius according to the weight of the ingredients of the chafing dish for reducing uric acid and improving immunity;
(3) mixing pericarpium Citri Reticulatae Chachiensis, Cordyceps and ramulus Mori, extracting with ethanol under 40KHz power with ultrasonic wave for 8min, and concentrating the extractive solution under reduced pressure until ethanol smell disappears to obtain active extract concentrated solution;
(4) slicing maca and phellinus igniarius, filling the sliced maca and phellinus igniarius into a hollow citrus main body, then soaking the hollow citrus main body into an active extract concentrated solution, sterilizing the hollow citrus main body at a high temperature of 121 ℃ for 25min, cooling the hollow citrus main body, inoculating 8% of high-temperature-resistant probiotics bacillus coagulans and lactobacillus, fermenting the hollow citrus main body at a temperature of 25 ℃ for 48h, taking out the hollow citrus main body, covering a top cover of the hollow citrus main body with the orange, drying the hollow citrus main body at a low temperature of 45 ℃ for 300min, taking out and packaging the hollow citrus main body to obtain the chafing dish ingredient for reducing uric acid and improving immunity.
Example 3
The chafing dish ingredient for reducing uric acid and improving immunity comprises the following raw materials by weight: 12g of citrus pith peel, 6g of cordyceps sinensis, 10g of ramulus mori, 12g of maca and 10g of phellinus igniarius;
the preparation method of the chafing dish ingredient for reducing uric acid and improving immunity specifically comprises the following steps:
(1) selecting mature oranges with uniform sizes, and opening the top of the mature oranges after the mature oranges are washed by running water to obtain an orange top cover; taking out citrus pulp to obtain a hollow citrus main body; punching holes on the citrus hollow main body to respectively obtain a citrus perforated peel and a citrus perforated hollow main body;
(2) weighing 12g of citrus pith peel, 6g of cordyceps sinensis, 10g of mulberry twig, 12g of maca and 10g of phellinus igniarius according to the weight of the ingredients of the chafing dish for reducing uric acid and improving immunity;
(3) mixing pericarpium Citri Reticulatae Chachiensis, Cordyceps and ramulus Mori, extracting with ethanol under 50KHz power with ultrasonic wave for 5min, and concentrating the extractive solution under reduced pressure until no ethanol smell exists to obtain active extract concentrated solution;
(4) slicing maca and phellinus igniarius, filling the sliced maca and phellinus igniarius into a hollow main body of citrus, then soaking the hollow main body of citrus in an active extract concentrated solution, sterilizing the hollow main body at a high temperature of 125 ℃ for 20min, cooling the hollow main body, inoculating 12% of high-temperature-resistant probiotics bacillus coagulans and lactic acid bacteria, fermenting the hollow main body at a temperature of 30 ℃ for 24h, taking out the hollow main body, covering a top cover of the citrus, drying the hollow main body at a low temperature of 50 ℃ for 240min, taking out and packaging the hollow main body to obtain the chafing dish ingredient for reducing uric acid and improving immunity.
Performance testing
After 40 male SPF-grade Kunming mice were adaptively fed for 7 days, they were randomly grouped into 30 hyperuricemia groups and 10 control groups, respectively.
The hyperuricemia group was administered 300mg/kg of Potassium Oxonate by intraperitoneal injection at one time, and then was randomly divided into 10 model groups, 10 allopurinol (40mg/kg) treatment groups, and 10 treatment groups. The treatment groups are fed with the uric acid reducing health preserving soup bag material prepared in the embodiment 1 of the invention, 300mg/kg per day, 3 times per day and 7 days continuously; the control group was fed with the same volume of saline.
After 7 days, the change in the blood uric acid level of each group of mice was measured. The results are shown in Table 1.
TABLE 17 days later the end blood uric acid concentrations in the mice experiment
As can be seen from Table 1, the serum uric acid level of the mice is obviously increased after the oteracil potassium is injected into the abdominal cavity, and the serum uric acid level is obviously different from that of the mice in a normal control group, thereby indicating that the molding is successful. After the hyperuricemia group is established, the uric acid reducing and immunity improving hotpot ingredients and allopurinol treatment of 40mg/kg in example 1 are respectively given, and the serum urea level is obviously lower than that of the model group.
The tests show that the chafing dish ingredient for reducing uric acid and improving immunity has a relatively obvious effect of reducing uric acid, and the effect is equivalent to that of allopurinol.
The previous description of the disclosed embodiments is provided to enable any person skilled in the art to make or use the present invention. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other embodiments without departing from the spirit or scope of the invention. Thus, the present invention is not intended to be limited to the embodiments shown herein but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.
Claims (8)
1. The chafing dish ingredient capable of reducing uric acid and improving immunity is characterized by comprising the following raw materials in parts by weight: 10-12 parts of citrus pith peel, 4-6 parts of cordyceps sinensis, 8-10 parts of mulberry twig, 12-15 parts of maca and 10-15 parts of phellinus igniarius.
2. A preparation method of a chafing dish ingredient for reducing uric acid and improving immunity is characterized by comprising the following steps:
(1) selecting mature oranges with uniform sizes, cleaning and opening the top of the mature oranges to obtain an orange top cover; taking out citrus pulp to obtain a hollow citrus main body; punching holes on the citrus hollow main body to respectively obtain a citrus perforated peel and a citrus perforated hollow main body;
(2) weighing the citrus reticulata blanco, the cordyceps sinensis, the ramulus mori, the maca and the phellinus igniarius according to the parts by weight of the uric acid reducing and immunity improving hotpot ingredients in the claim 1;
(3) mixing pericarpium Citri Reticulatae Chachiensis, Cordyceps and ramulus Mori, extracting with ultrasonic wave, and concentrating the extractive solution under reduced pressure to obtain active extract concentrated solution;
(4) slicing maca and phellinus igniarius, filling the sliced maca and phellinus igniarius into a hollow main body of an orange, then soaking the orange in an active extract concentrated solution, sterilizing at high temperature, inoculating high-temperature-resistant probiotics after cooling, taking out after fermentation, covering a top cover of the orange, drying at low temperature, taking out and packaging to obtain the uric acid reducing and immunity improving hotpot ingredient.
3. The preparation method of chafing dish ingredient for reducing uric acid and improving immunity according to claim 2, wherein in the step (3), the solvent for ultrasonic extraction is ethanol, the power is 40-50KHz, and the time is 5-8 min.
4. The method for preparing the chafing dish ingredient capable of reducing uric acid and improving immunity according to claim 2, wherein in the step (3), the concentration under reduced pressure is carried out until the extract has no ethanol smell.
5. The method for preparing chafing dish ingredient for lowering uric acid and improving immunity as claimed in claim 2, wherein in the step (4), the temperature for high temperature sterilization is 121-125 ℃ for 20-25 min.
6. The preparation method of the chafing dish ingredient for reducing uric acid and improving immunity according to claim 2, wherein in the step (4), the high-temperature resistant probiotics are bacillus coagulans and lactic acid bacteria, and the inoculation amount of the bacillus coagulans and the lactic acid bacteria is 8-12%.
7. The preparation method of the chafing dish ingredient for reducing uric acid and improving immunity according to claim 2, wherein in the step (4), the fermentation temperature is 25-30 ℃ and the fermentation time is 24-48 h.
8. The method for preparing chafing dish ingredient for lowering uric acid and improving immunity as claimed in claim 2, wherein in the step (4), the temperature for low-temperature drying is 45-50 ℃ for 300 min.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111480327.XA CN114176212A (en) | 2021-12-06 | 2021-12-06 | Chafing dish ingredient capable of reducing uric acid and improving immunity and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111480327.XA CN114176212A (en) | 2021-12-06 | 2021-12-06 | Chafing dish ingredient capable of reducing uric acid and improving immunity and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114176212A true CN114176212A (en) | 2022-03-15 |
Family
ID=80603502
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111480327.XA Pending CN114176212A (en) | 2021-12-06 | 2021-12-06 | Chafing dish ingredient capable of reducing uric acid and improving immunity and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114176212A (en) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1382478A (en) * | 2002-05-14 | 2002-12-04 | 南京大学 | Extract of mulberry twig and its extracting process and novel usage |
CN107569654A (en) * | 2017-10-04 | 2018-01-12 | 南京正宽医药科技有限公司 | A kind of extracting method of composition containing maca and maca |
CN108379305A (en) * | 2018-04-24 | 2018-08-10 | 吉林大学 | Application of the Phellinus water extract in anti-uric acid |
CN108634066A (en) * | 2018-07-02 | 2018-10-12 | 衢州市恒鑫生物科技有限公司 | A kind of dry tea packet |
CN108926580A (en) * | 2018-08-22 | 2018-12-04 | 江苏国桢生物科技有限公司 | A kind of Cordyceps militaris extracting solution and preparation method thereof |
CN109394895A (en) * | 2018-11-26 | 2019-03-01 | 吉林珍本堂生物科技集团有限公司 | A kind of yellow mulberry tea and preparation method |
CN110604202A (en) * | 2019-11-11 | 2019-12-24 | 广东省农业科学院蚕业与农产品加工研究所 | Preparation method of mulberry leaf and exocarpium citri grandis health tea |
WO2020031961A1 (en) * | 2018-08-10 | 2020-02-13 | サントリーホールディングス株式会社 | Composition for promoting uric acid excretion, composition for inhibiting urat1 and composition for lowering blood uric acid level |
-
2021
- 2021-12-06 CN CN202111480327.XA patent/CN114176212A/en active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1382478A (en) * | 2002-05-14 | 2002-12-04 | 南京大学 | Extract of mulberry twig and its extracting process and novel usage |
CN107569654A (en) * | 2017-10-04 | 2018-01-12 | 南京正宽医药科技有限公司 | A kind of extracting method of composition containing maca and maca |
CN108379305A (en) * | 2018-04-24 | 2018-08-10 | 吉林大学 | Application of the Phellinus water extract in anti-uric acid |
CN108634066A (en) * | 2018-07-02 | 2018-10-12 | 衢州市恒鑫生物科技有限公司 | A kind of dry tea packet |
WO2020031961A1 (en) * | 2018-08-10 | 2020-02-13 | サントリーホールディングス株式会社 | Composition for promoting uric acid excretion, composition for inhibiting urat1 and composition for lowering blood uric acid level |
CN108926580A (en) * | 2018-08-22 | 2018-12-04 | 江苏国桢生物科技有限公司 | A kind of Cordyceps militaris extracting solution and preparation method thereof |
CN109394895A (en) * | 2018-11-26 | 2019-03-01 | 吉林珍本堂生物科技集团有限公司 | A kind of yellow mulberry tea and preparation method |
CN110604202A (en) * | 2019-11-11 | 2019-12-24 | 广东省农业科学院蚕业与农产品加工研究所 | Preparation method of mulberry leaf and exocarpium citri grandis health tea |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101090284B1 (en) | Tonic comprising red ginseng and deer antlers extracts and manufacturing method thereof | |
CN103054113B (en) | Composite fruit-vegetable juice beverage with blood sugar decreasing effect | |
CN102511869B (en) | Thickened red jujube ginger pulp | |
CN103039789A (en) | Compound medlar and Chinese chestnut health-care food and preparation method thereof | |
CN1792268A (en) | Making method of health-care beverage for efficient preventing and treating asthma | |
CN104305427A (en) | Grape and red tea fungus drink | |
CN103361223B (en) | Multiplex healthy wine and preparation method thereof | |
CN106858215A (en) | A kind of passion fruit composite beverage | |
CN103719948A (en) | Medical pork tripe soup capable of tonifying spleen and promoting appetite | |
CN103877122A (en) | Production method and donkey-hide gelatin of Chinese herbal donkey-hide gelatin material | |
CN103704348A (en) | Donkey milk powder formula for boosting brain, nourishing blood and improving resistance based on homology of medicine and food | |
CN103695275B (en) | Method for preparing Korean-ginseng and sea cucumber wine | |
CN102511876B (en) | Hawthorn red jujube thick syrup and production process thereof | |
CN104287045A (en) | Large green date and tea fungus beverage | |
KR101260854B1 (en) | Method for producing pickles of tree ear | |
CN104431125A (en) | Sea-buckthorn honey tea and preparation method thereof | |
CN104017715A (en) | Passion fruit vinegar and preparation method thereof | |
CN105695236A (en) | Formula and production process for health maintenance and healthcare wine | |
CN105985895A (en) | Health-preserving wine and preparation technique thereof | |
CN109527577A (en) | A kind of composition with sobering up and liver protecting functions | |
CN104906140A (en) | Donkey-hide gelatin, a preparation method and associated equipment | |
CN104726320B (en) | A kind of fig honey vinegar and preparation method | |
CN114176212A (en) | Chafing dish ingredient capable of reducing uric acid and improving immunity and preparation method thereof | |
CN102511882A (en) | Red jujube thick syrup beneficial for improving growth and development | |
CN103478696B (en) | Tremella-containing cool and refreshing nourishing food and production method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |